HomeCompareRCRTW vs JNJ

RCRTW vs JNJ: Dividend Comparison 2026

RCRTW yields 45454.55% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RCRTW wins by $1.8518439162416517e+23M in total portfolio value
10 years
RCRTW
RCRTW
● Live price
45454.55%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8518439162416517e+23M
Annual income
$184,386,416,447,528,030,000,000,000,000.00
Full RCRTW calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RCRTW vs JNJ

📍 RCRTW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRCRTWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RCRTW + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RCRTW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RCRTW
Annual income on $10K today (after 15% tax)
$3,863,636.36/yr
After 10yr DRIP, annual income (after tax)
$156,728,453,980,398,820,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RCRTW beats the other by $156,728,453,980,398,820,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RCRTW + JNJ for your $10,000?

RCRTW: 50%JNJ: 50%
100% JNJ50/50100% RCRTW
Portfolio after 10yr
$9.259219581208259e+22M
Annual income
$92,193,208,223,764,020,000,000,000,000.00/yr
Blended yield
99.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RCRTW
No analyst data
Altman Z
-10.5
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RCRTW buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRCRTWJNJ
Forward yield45454.55%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.8518439162416517e+23M$30.3K
Annual income after 10y$184,386,416,447,528,030,000,000,000,000.00$4,689.40
Total dividends collected$1.851319904100255e+23M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RCRTW vs JNJ ($10,000, DRIP)

YearRCRTW PortfolioRCRTW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$4,556,155$4,545,454.55$10,592$272.30+$4.55MRCRTW
2$1,940,369,795$1,935,494,709.20$11,289$357.73+$1940.36MRCRTW
3$772,437,161,927$770,360,966,246.63$12,123$472.89+$772437.15MRCRTW
4$287,435,060,178,011$286,608,552,414,749.56$13,141$629.86+$287435060.16MRCRTW
5$99,981,569,689,116,400$99,674,014,174,725,920.00$14,408$846.81+$99981569689.10MRCRTW
6$32,509,470,002,941,550,000$32,402,489,723,374,190,000.00$16,021$1,151.60+$32509470002941.54MRCRTW
7$9,881,345,376,928,724,000,000$9,846,560,244,025,577,000,000.00$18,122$1,588.22+$9881345376928724.00MRCRTW
8$2,807,666,349,987,340,400,000,000$2,797,093,310,434,026,500,000,000.00$20,930$2,228.20+$2807666349987340288.00MRCRTW
9$745,771,193,118,814,000,000,000,000$742,766,990,124,327,600,000,000,000.00$24,792$3,191.91+$745771193118813978624.00MRCRTW
10$185,184,391,624,165,170,000,000,000,000$184,386,416,447,528,030,000,000,000,000.00$30,274$4,689.40+$1.8518439162416517e+23MRCRTW

RCRTW vs JNJ: Complete Analysis 2026

RCRTWStock

Recruiter.com Group, Inc. operates an on-demand recruiting platform in the United States and internationally. It offers consulting and staffing services for the placement of professional recruiters; and consulting and staffing personnel services to employers. The company also provides referrals of qualified candidates to employers; and subscription to its web-based platforms that help employers recruit talent. In addition, it offers sponsorship of digital newsletters, online content promotion, social media distribution, banner advertising, and other branded electronic communications services for businesses; and resume distribution services, which involve promoting these job seekers' profiles and resumes to assist with their procuring employment, and upskilling and training for individuals to assist with career development and advancement. The company was incorporated in 2008 and is headquartered in New York, New York.

Full RCRTW Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RCRTW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RCRTW vs SCHDRCRTW vs JEPIRCRTW vs ORCRTW vs KORCRTW vs MAINRCRTW vs ABBVRCRTW vs MRKRCRTW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.